JP Morgan Chase
CRVO icon

JP Morgan Chase’s CervoMed CRVO Stock Holding History

JP Morgan Chase’s Portfolio CRVO Stock Details CRVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,400
Closed -$26.9K – 7591
2025
Q4 		$26.9K Buy
3,400
+1,425
+72% +$11.4K ﹤0.01% 6438
2025
Q3 		$16K Buy
+1,975
New +$16.9K ﹤0.01% 6533
2025
Q2 		– Sell
-2,843
Closed -$26K – 7168
2025
Q1 		$26K Sell
2,843
-11,621
-80% -$44.3K ﹤0.01% 6079
2024
Q4 		$33.8K Buy
14,464
+10,352
+252% +$101K ﹤0.01% 6130
2024
Q3 		$60K Buy
4,112
+1,810
+79% +$28K ﹤0.01% 5926
2024
Q2 		$39.4K Buy
+2,302
New +$50.3K ﹤0.01% 5949
2022
Q2 		– Sell
-113
Closed -$106K – 6520
2022
Q1 		$106K Buy
+113
New +$2.24K ﹤0.01% 5476

Other funds holding CRVO

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
CFG
Citizens Financial Group Providence, Rhode Island $8.3B AUM 27.66% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

JP Morgan Chase's CRVO Position: Q1 2026 in Review

JP Morgan Chase sold out of CervoMed (CRVO) in Q1 2026, closing a stake of 3,400 shares — an estimated $26.9K sold.

JP Morgan Chase first reported a position in CRVO in Q1 2022 and held it in 7 quarters. The position peaked at $106K in Q1 2022. 36 funds tracked by Wall St. Rank hold CRVO as of Q1 2026.

  • JP Morgan Chase reported no remaining CervoMed position as of Q1 2026 after selling out during the quarter.
  • JP Morgan Chase sold 3,400 CervoMed shares in Q1 2026, an estimated $26.9K.
  • JP Morgan Chase first reported a position in CervoMed in Q1 2022 and held it in 7 quarters.
  • JP Morgan Chase's CervoMed position peaked at $106K in Q1 2022.
  • 36 funds tracked by Wall St. Rank held CervoMed as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.